Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Receivables (2016 - 2025)

Ptc Therapeutics (PTCT) has 13 years of Receivables data on record, last reported at $181.6 million in Q4 2025.

  • For Q4 2025, Receivables rose 14.55% year-over-year to $181.6 million; the TTM value through Dec 2025 reached $181.6 million, up 14.55%, while the annual FY2025 figure was $181.6 million, 14.55% up from the prior year.
  • Receivables reached $181.6 million in Q4 2025 per PTCT's latest filing, down from $203.1 million in the prior quarter.
  • Across five years, Receivables topped out at $210.5 million in Q1 2025 and bottomed at $78.8 million in Q2 2021.
  • Average Receivables over 5 years is $159.0 million, with a median of $164.1 million recorded in 2023.
  • Peak YoY movement for Receivables: skyrocketed 78.86% in 2021, then decreased 1.69% in 2024.
  • A 5-year view of Receivables shows it stood at $110.5 million in 2021, then skyrocketed by 40.88% to $155.6 million in 2022, then grew by 3.48% to $161.0 million in 2023, then decreased by 1.53% to $158.6 million in 2024, then grew by 14.55% to $181.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $181.6 million in Q4 2025, $203.1 million in Q3 2025, and $196.1 million in Q2 2025.